跳至主要内容
临床试验/JPRN-UMIN000005440
JPRN-UMIN000005440招募中1 期

Phase I study of XELOXIRI(CPT-11,L-OHP, capecitabine) with Bevacizumab in patients with unresectable advanced/metastatic colorectal cancer - Phase I study ofXELOXIRI with Bevacizumab for metastatic coloectal cancer

Sapporo Medical University School of Medicine Dept. of Internal Medicine(4)0 个研究点目标入组 24 人开始时间: 2011年4月14日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Prior severe drug allergy. 2) Synchronous and/or metachronous multiple cancers. 3) Prior chemotherapy with CPT-11,L-OHP, capecitabeine or Bevacizumab containing regimen. 4)Surgical procedure within 28 days prior to enrollment. 5) Severe comorbidity - Severe pulmonary dysfunction - Uncontrolled DM - Uncontrolled HT - Severe cardiovascular disease - Cirrhosis and liver failure - Renal failure 6) Sensory neuropathy 7) Severe diarrhea 8) Active infection 9) Symptomatic pleural effusion or ascites 10)Contraindications to CPT-11, L-OHP, capecitabeine or Bevacizumab 11) Concerning pregnancy 12) The investigator considers not suitable for the study.

研究者

发起方
Sapporo Medical University School of Medicine Dept. of Internal Medicine(4)

相似试验